- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02825628
Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC) (CRPC)
A Randomised, Double-blind, Dose Finding, Repeat Dose Phase II Multicentre Study of ODX for the Treatment of Patients With Castration Resistant Prostate Cancer (CRPC) and Skeletal Metastases
This is a phase II randomised, double-blind, dose finding, repeat dose Phase II multicentre study of ODX for the treatment of patients with castration resistant prostate cancer (CRPC) and skeletal metastases.
The primary objective is to evaluate the relative change from baseline in response markers related to bone metabolism (alkaline phosphatase (B-ALP) and S P1NP) at 12 weeks of three different doses of ODX (3.0, 6.0 and 9.0 mg/kg ODX).
Study Overview
Detailed Description
Males, diagnosed with CRPC, who fulfil the inclusion criteria and does not have any exclusion criteria, will be asked to participate in the study. The subject will be informed orally and in writing about the study procedures and give written informed consent, prior to study start.
At the screening visit the following examinations are performed: Physical examination, medical history and concomitant medication. Heart rate, blood pressure, weight, height, body temperature and respiratory rate are measured. Blood samples are drawn and urine sample is collected. ECG is recorded. Bone scan and diagnostic CT scan are also performed. At the next visit, baseline, the subject is examined physically and heart rate, blood pressure, weight, body temperature and respiratory rate are measured, ECG is recorded, blood samples drawn and urine sample collected. FACT-P and EQ-5D-5L (European Quality of Life - 5 Dimensions with 5 levels) questionnaire are filled out by the subject. Adverse events and concomitant medication is documented and the first dose of the investigational product is given.
The subject is surveyed for 3 hours at the hospital.
The duration of the study for the individual subject will be approximately 20 weeks from screening to the follow-up visit 2 weeks after the last dose. Each subject will receive 10 doses of investigational product. After the follow-up visit, the subject enters to long-term follow-up phase which lasts approximately 2 years.
A Data Monitoring Committee (DMC) will be designated and will be responsible to monitor/review all study related safety data. After review of safety data the DMC will provide recommendation as to whether the dose escalation can proceed as planned according to the protocol.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Tallinn, Estonia, 10138
- East Tallinn Central Hospital
-
Tartu, Estonia, 51014
- Tartu University Hospital
-
-
-
-
-
Tampere, Finland, 33520
- Tampere University Hospital, Urology Clinic
-
-
-
-
-
Daugavpils, Latvia, 5401
- Latgales Urology Center
-
Riga, Latvia, 1002
- Pauls Strandins Clinical University Hospital
-
-
-
-
-
Stockholm, Sweden, 118 83
- Urology Clinic, Sodersjukhuset AB
-
Umeå, Sweden, 901 85
- Oncology Clinic, Norrlands Universitetssjukhus
-
Örebro, Sweden, 70185
- Orebro University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years at the time of signing the informed consent form
- Histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate
- Evidence of disease progression based on changes in metastatic bone disease (≥2 bone lesions compared to a prior examination) in bone scan and/or other imaging modality AND/OR evidence of PSA progression in the three consecutive determinations at minimum of 1 week intervals
- Castrate level of serum testosterone ≤1.7 nmol/L
- Performance status ECOG 0-2
Laboratory requirements:
Haematology:
Neutrophils ≥ 1.5 x 109/l Haemoglobin ≥ 90 g/l Platelets ≥ 100 x 109/l
Hepatic function:
Total S-bilirubin ≤ 1.5 times the upper limit of normal (ULN) AST (SGOT) / ALT (SGPT) ≤ 2.5 times ULN or ≤ 5 times ULN in patients with known liver metastases
Renal function:
S-creatinine (S-Cr)≤ 1.5 times ULN
- No evidence (≤ 5 years) of prior malignancies (except successfully treated basal cell or squamous cell carcinoma of the skin)
- Able to adhere to the study visit schedule and other protocol requirements Life expectancy ≥6 months
Exclusion Criteria:
- Concurrent use of other anti-cancer agents or treatments, with the following exception: a stable dose of Luteinizing Hormone-Releasing Hormone (LHRH) agonist/antagonist or polyestradiol phosphate. Washout period: bicalutamide 6 weeks; flutamide 4 weeks; abiraterone / enzalutamide 6 weeks, chemotherapy 4 weeks; Radium-223 4 weeks; Strontium-89 or Samarium-153 6 months.
- Any treatment modalities involving palliative radiation therapy or major surgery within 4 weeks prior to treatment in this study
- Simultaneous participation in any other study involving investigational drugs or having participated in a study less than 4 weeks prior to start of study treatment
- Any condition, including the presence of laboratory abnormalities, which confounds the ability to interpret data from the study or places the patient at unacceptable risk if he participates in the study
- Known brain metastases
- Dental surgery (dental extraction), periodontal disease, local trauma including poorly fitting dentures within 6 months prior to the first dose of study drug
- Treatment with bisphosphonates or denosumab within 4 weeks prior to first dose of study medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Osteodex 3.0 mg/kg
formulation: solution for infusion route of administration: intravenous infusion
|
formulation: solution for infusion route of administration: intravenous infusion
Other Names:
|
Experimental: Osteodex 6.0 mg/kg
formulation: solution for infusion route of administration: intravenous infusion
|
formulation: solution for infusion route of administration: intravenous infusion
Other Names:
|
Experimental: Osteodex 9.0 mg/kg
formulation: solution for infusion route of administration: intravenous infusion
|
formulation: solution for infusion route of administration: intravenous infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Relative change from baseline in response markers related to bone metabolism (B-ALP and S P1NP).
Time Frame: Baseline and 20 weeks of treatment
|
Baseline and 20 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression free survival, defined as the time from study entry to the date of disease progression or death from any cause.
Time Frame: Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks
|
Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks
|
Overall survival, defined as the time from randomisation to the date of death from any cause.
Time Frame: Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks
|
Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks
|
Change from baseline in response markers related to bone metabolism (B-ALP and S P1NP) at each time point sampled (except 12 weeks).
Time Frame: Baseline and 20 weeks of treatment
|
Baseline and 20 weeks of treatment
|
Change from baseline in response markers related to bone metabolism (Serum C-Terminal Telopeptide (S-CTX) and osteocalcin) at each time point sampled.
Time Frame: Baseline and 20 weeks of treatment
|
Baseline and 20 weeks of treatment
|
Change from baseline in Prostate Specific Antigen (PSA) at each time point sampled.
Time Frame: Baseline and 20 weeks of treatment
|
Baseline and 20 weeks of treatment
|
Time to PSA progression
Time Frame: Baseline and 20 weeks of treatment
|
Baseline and 20 weeks of treatment
|
Time to ALP progression
Time Frame: Baseline and 20 weeks of treatment
|
Baseline and 20 weeks of treatment
|
Time to P1NP progression
Time Frame: Baseline and 20 weeks of treatment
|
Baseline and 20 weeks of treatment
|
Time to progression in bone
Time Frame: Baseline and 20 weeks of treatment
|
Baseline and 20 weeks of treatment
|
Time to progression in soft tissue
Time Frame: Baseline and 20 weeks of treatment
|
Baseline and 20 weeks of treatment
|
Use of analgesics as reported by the patient during treatment and follow-up
Time Frame: Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks
|
Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks
|
Therapy response based on changes from baseline according to Response Evaluation Criteria In Solid Tumors (RECIST) based on diagnostic CT in patients with measurable soft tissue metastases.
Time Frame: Baseline and 20 weeks of treatment
|
Baseline and 20 weeks of treatment
|
Changes from baseline in bone metastasis by means of bone scan at each time point examined.
Time Frame: Baseline and 20 weeks of treatment
|
Baseline and 20 weeks of treatment
|
Occurrence of symptomatic skeletal events
Time Frame: Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks
|
Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks
|
Pain (FACT-P questionnaire)
Time Frame: Baseline and 20 weeks of treatment
|
Baseline and 20 weeks of treatment
|
Pain (EQ-5D-5L questionnaire)
Time Frame: Baseline and 20 weeks of treatment
|
Baseline and 20 weeks of treatment
|
Quality of life (EQ-5D-5L questionnaire)
Time Frame: Baseline and 20 weeks of treatment
|
Baseline and 20 weeks of treatment
|
Incidence, causality and intensity of Adverse Events (AEs)
Time Frame: Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks
|
Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks
|
Dose and duration of medications required for the treatment of AEs
Time Frame: Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks
|
Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Anders Holmberg, MD, DexTech Medical AB
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ODX-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer Metastatic
-
Imperial College LondonWellcome Trust; Imperial Clinical Trials Unit (ICTU)CompletedProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Metastatic Prostate Carcinoma in the Soft Tissue | Non-metastatic Prostate CancerUnited Kingdom
-
Dana MathewsWithdrawnProstate Cancer | Prostate Cancer Metastatic | Prostate Cancer Metastatic to BoneUnited States
-
The University of Texas Health Science Center at...WithdrawnMetastatic Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma | Castrate Resistant Prostate CancerUnited States
-
Herlev and Gentofte HospitalBristol-Myers SquibbRecruitingProstate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer | Prostate Cancer Stage IVDenmark
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Bellicum PharmaceuticalsSuspendedMetastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Dana-Farber Cancer InstituteEpizyme, Inc.; PfizerRecruitingMetastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Tavanta TherapeuticsCompletedMetastatic Prostate Cancer | Metastatic Castration-sensitive Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States, Spain, United Kingdom, Hungary, France, Poland, Puerto Rico, Sweden
-
Memorial Sloan Kettering Cancer CenterProgenics Pharmaceuticals, Inc.RecruitingProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate NeoplasmUnited States
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
Clinical Trials on Osteodex
-
DexTech Medical ABCompletedProstate Cancer MetastaticSweden
-
DexTech Medical ABTerminatedProstate Cancer MetastaticSweden